I would normally tend to agree with, but I hold personal knowledge about two of their former product lines and knew day one, they would likely fail. Which at some point, management also knew they had to change direction and dump them.
As I posted earlier, I didn't like their "products" when I first looked at them a few years ago. What first caught my attention was the OS count and the makeup of the team at that time and the fact that they spent years cleaning up the financials. The last OTC that I played over updating financials pulled me a seven-figure profit. When you see an OTC spending over $60K in legal and accounting, it means they normally have a bigger game plan than the "little" people understand. Now add in the new product line and you more than have my attention.
If you carefully consider the information provided by various posters and links, it's clear that no one is artificially inflating this stock. The long-term investors here are fully aware of the risks and the absence of guarantees regarding FDA approvals, securing contracts, or avoiding stock dilution. Nevertheless, based on the actions I've observed from management over the last three years, I will say I like the odds.
As far as not adding up, it wouldn't if you don't take the time to review the facts and do your OWN research.
Bullish
News 
Market Data 
Discover 
AI
